Nasdaq
$10.83▲ 1.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $54.0MShares out 5.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.14Regular26.10.15 03:364Ownership#●●●#●●●
MiNK Therapeutics, Inc.
Director Jennifer Buell of MiNK Therapeutics reported a change in beneficial ownership of company securities on October 11, 2026. This filing is a Form 4 report detailing the insider's updated stock holdings.…more
$10.83+1.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 21:36144Ownership
MiNK Therapeutics, Inc.
Jennifer Buell of MiNK Therapeutics filed an SEC Form 144 on October 13, 2026, reporting a proposed sale of company securities. This filing serves as a notification of an insider's plan to dispose of shares.…more
$10.83+1.05%vs prev closeView filingShare - 9.2Regular26.09.03 00:104Ownership
MiNK Therapeutics, Inc.
Ulf Wiinberg, an insider at MiNK Therapeutics, reported a change in his beneficial ownership of company securities as of September 1, 2026. This filing serves as an official disclosure to the SEC regarding the change in the insider's stock holdings.…more
$10.83+1.05%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2Pre-market26.10.02 22:00#●●●#●●●
MiNK Therapeutics to Present Cancer Research Data at SITC 2026
MiNK Therapeutics will present preclinical data on treatment-resistant colorectal cancer and tumor cell clearance at the upcoming SITC 2026 meeting. The presentations aim to highlight the therapeutic potential of the company's iNKT cell therapy platform.…more
$10.83+1.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 20:58
●●●●●●●● ●●●●● ●●●●●●
MiNK Therapeutics' agenT-797 has been selected as the cell platform for a research team led by Draper for the ARPA-H room-temperature storage program. While this highlights technical recognition, the lack of specific financial terms or revenue impact results in a neutral outlook.…more
$10.83+1.05%vs prev closeShareBenzinga - 8.13Pre-market26.08.13 20:30
●●●●●●●● ●●●●● ●●●●●●
MiNK Therapeutics reported promising early observations from its Phase 2 trial of agenT-797 in acute lung injury, showing improved patient outcomes. The company also launched a paid named-patient access program in Brazil to expand treatment availability and generate revenue.…more
$10.83+1.05%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report